|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 45/06 | (2013.01) |
| A61K 31/365 | (2006.01) | ||
| A61K 31/404 | (2006.01) | ||
| A61K 31/553 | (2013.01) | ||
| A61K 31/53 | (2013.01) | ||
| A61K 31/437 | (2006.01) | ||
| A61K 31/551 | (2013.01) | ||
| A61K 31/44 | (2006.01) | ||
| A61K 31/5377 | (2013.01) | ||
| A61K 31/444 | (2006.01) | ||
| A61K 31/4709 | (2006.01) | ||
| A61K 31/404 | (2013.01) | ||
| A61K 31/496 | (2006.01) | ||
| A61K 31/44 | (2013.01) | ||
| A61K 31/497 | (2006.01) | ||
| A61K 31/4709 | (2013.01) | ||
| A61K 31/444 | (2013.01) | ||
| A61K 31/5025 | (2006.01) | ||
| A61K 31/365 | (2013.01) | ||
| A61K 31/53 | (2006.01) | ||
| A61K 31/497 | (2013.01) | ||
| A61K 31/5377 | (2006.01) | ||
| A61K 31/5025 | (2013.01) | ||
| A61K 31/551 | (2006.01) | ||
| A61K 31/496 | (2013.01) | ||
| A61K 31/553 | (2006.01) | ||
| A61K 31/437 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07D 251/52 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| C07D 403/14 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07D 401/14 | (2013.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 35/02 | (2018.01) | ||
| C07D 251/52 | (2006.01) | ||
| C07D 401/14 | (2006.01) | ||
| C07D 403/14 | (2006.01) |
| (11) | Patento numeris | 3419593 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16816810.2 |
| Europos patento paraiškos padavimo data | 2016-12-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-01-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2022-03-23 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/064615 |
| Data | 2016-12-02 |
| (87) | Numeris | WO 2017/146794 |
| Data | 2017-08-31 |
| (30) | Numeris | Data | Šalis |
| 201662300673 P | 2016-02-26 | US |
| (72) |
AMATANGELO, Michael , US
HU, Xiaolan , US
THAKURTA, Anjan , US
CHOE, Sung Eun , US
WU, Bin , US
|
| (73) |
Celgene Corporation ,
86 Morris Avenue, Summit, NJ 07901,
US
Les Laboratoires Servier , 50 rue Carnot, 92284 Suresnes Cedex, FR |
| (54) | ENASIDENIB FOR USE IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA |
| ENASIDENIB FOR USE IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA |